Text
Corporate acquisitions are strategic actions that loom large in the minds of many senior managers. Despite decades of study, little systematic research exists on a central question: Why do the acquisitions of some firms perform better than those of others? The work that has examined this question has mostly focused on deal-specific variables (i.e., how the acquisitions are conducted).
In this article, the authors highlight a firm-specific, marketing-driven variable-namely, product capital-that affects acquisition performance and predicts which firms are better positioned to acquire in the first place. The authors also present a mechanism by which product capital affects performance-namely, through acquirers' superior selection and deployment of targets' innovation potential. This article shows that firms with high product capital (i.e., those with greater product development and support assets) make smarter acquisition decisions.
Such firms are better at selecting targets with innovation potential and then deploying this potential to gain competitive advantage. The performance consequences of this superiority in the selection and deployment of target firms manifest in the long-term financial rewards to the acquiring firm. The results of an analysis of acquisitions in the pharmaceutical industry across seven countries and over 11 years (1992-2002) provide empirical support for the arguments.
| Call Number | Location | Available |
|---|---|---|
| JMR4407 | PSB lt.dasar - Pascasarjana | 1 |
| Penerbit | Chicago: American Marketing Association 2007 |
|---|---|
| Edisi | Vol. 44, No. 1 (Feb., 2007), pp. 57-72 |
| Subjek | Brand equity Business strategy Innovation Strategy Mergers and Acquisitions Stock Market Returns Long-term performance Product Capital Strategic Acquisitions |
| ISBN/ISSN | 0022-2437 |
| Klasifikasi | NONE |
| Deskripsi Fisik | 16 p. |
| Info Detail Spesifik | Journal of Marketing |
| Other Version/Related | Tidak tersedia versi lain |
| Lampiran Berkas |